CEO Jonathan Mazelsky was paid $14,580,122 in fiscal year 2025, ↑ up 12.1% from fiscal year 2024, the 50th percentile of its disclosed peer group (SEC filing 0000874716-26-000064 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$14,580,122 ↑ Jonathan Mazelsky total, FY2025 | 50th CEO pay percentile vs peers | 218:1 CEO-to-median pay ratio | 94.22% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
IDXX's next annual pay disclosure, estimated March 26, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Jonathan Mazelsky | $1,150,000 | $0 | $5,399,881 | $5,400,001 | $2,593,000 | $0 | $37,240 | $14,580,122 |
| President and Chief Executive Officer | ||||||||
| Michael Lane | 594,054 | 0 | 1,349,855 | 1,349,949 | 627,270 | 0 | 98,288 | 4,019,416 |
| Executive Vice President and General Manager, CAG Diagnostics Business Unit | ||||||||
| Tina Hunt | 594,054 | 0 | 1,349,855 | 1,349,949 | 627,270 | 0 | 24,165 | 3,945,293 |
| Executive Vice President, Global Strategy and Commercial | ||||||||
| Martin Smith | 594,054 | 0 | 1,349,855 | 1,349,949 | 627,270 | 0 | 23,406 | 3,944,534 |
| Executive Vice President and Chief Technology Officer, R&D, Global Operations, Information Technology and Information Security | ||||||||
| Andrew Emerson | 531,146 | 0 | 949,864 | 949,941 | 577,500 | 0 | 24,620 | 3,033,071 |
| Executive Vice President, Chief Financial Officer and Treasurer | ||||||||
| Brian McKeon | 293,404 | 0 | 0 | 0 | 0 | 0 | 58,276 | 351,680 |
| Former Executive Vice President, Chief Financial Officer and Treasurer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Jonathan Mazelsky | $14,580,122 | $13,007,051 | $11,519,309 | ↑ +1,573,071 |
| Michael Lane | 4,019,416 | 3,726,323 | 2,921,361 | ↑ +293,093 |
| Tina Hunt | 3,945,293 | 3,730,700 | 3,570,793 | ↑ +214,593 |
| Martin Smith | 3,944,534 | 3,719,059 | — | ↑ +225,475 |
| Andrew Emerson | 3,033,071 | — | — | — |
| Brian McKeon | 351,680 | 3,892,748 | 3,845,065 | ↓ −3,541,068 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read IDEXX Laboratories's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper IDXX reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name IDXX as a peer is temporarily unavailable — recheck shortly.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Asha S. Collins, PhD | Former director (through FY2025) | $22,500 |
| Bruce L. Claflin | Independent Director | $347,469 |
| Daniel M. Junius | Independent Director | $369,969 |
| Irene Chang Britt | Independent Director | $372,469 |
| Joseph L. (Jay) Hooley | Independent Director | $251,105 |
| Karen Peacock | Independent Director | $168,083 |
| Lawrence D. Kingsley | Chair of the Board | $499,842 |
| M. Anne Szostak | Independent Director | $372,469 |
| Sam Samad | Independent Director | $347,469 |
| Sophie V. Vandebroek, PhD | Independent Director | $339,969 |
| Stuart M. Essig, PhD | Independent Director | $354,969 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Joseph L. (Jay) Hooley | Director | 2026-04-30 | A | 43 | $561 | $24,114 | Deferred share award | Form 4 ↗ |
| Joseph L. (Jay) Hooley | Director | 2026-05-07 | A | 158 | 0 | 0 | Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-07 | D | 82 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-07 | D | 257 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-07 | A | 82 | 0 | 0 | Common | Form 4 ↗ |
| Karen Peacock | Director | 2026-05-07 | D | 101 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Karen Peacock | Director | 2026-05-07 | A | 101 | 0 | 0 | Common | Form 4 ↗ |
| Sophie V. Vandebroek, PhD | Director | 2026-05-07 | D | 257 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sophie V. Vandebroek, PhD | Director | 2026-05-07 | A | 257 | 0 | 0 | Common | Form 4 ↗ |
| Daniel M. Junius | Director | 2026-05-07 | A | 257 | 0 | 0 | Common | Form 4 ↗ |
| M. Anne Szostak | Director | 2026-05-07 | A | 257 | 0 | 0 | Common | Form 4 ↗ |
| Joseph L. (Jay) Hooley | Director | 2026-05-07 | D | 158 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel M. Junius | Director | 2026-05-07 | D | 257 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-07 | A | 257 | 0 | 0 | Common | Form 4 ↗ |
| M. Anne Szostak | Director | 2026-05-07 | D | 257 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-05-12 | — | 7,074 | — | — | 9 insiders, 20 accrual rows | ||
| George Fennell | Executive Vice President | 2026-06-01 | D | 639 | — | — | Derivative, Class A Common | Form 4 ↗ |
| George Fennell | Executive Vice President | 2026-06-01 | D | 284 | 567 | 160,968 | Common | Form 4 ↗ |
| George Fennell | Executive Vice President | 2026-06-01 | A | 639 | 0 | 0 | Common | Form 4 ↗ |
| Joseph L. (Jay) Hooley | Director | 2026-07-30 | A | 49 | 559 | 27,381 | Deferred share award | Form 4 ↗ |
| Andrew Emerson | EVP, CFO and Treasurer | 2026-08-20 | D | 265 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Emerson | EVP, CFO and Treasurer | 2026-08-20 | D | 86 | 0 | 0 | Common | Form 4 ↗ |
| Andrew Emerson | EVP, CFO and Treasurer | 2026-08-20 | A | 265 | 178 | 47,239 | Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-09-04 | D | 2,203 | 532 | 1,172,178 | Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-09-04 | D | 2,203 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-09-04 | A | 2,203 | 114 | 251,517 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Joseph L. (Jay) Hooley | Director | 2026-04-30 | A | 43 | $561 | $24,114 | Deferred share award | Form 4 ↗ |
| Joseph L. (Jay) Hooley | Director | 2026-05-07 | A | 158 | 0 | 0 | Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-07 | D | 82 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-07 | D | 257 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-07 | A | 82 | 0 | 0 | Common | Form 4 ↗ |
| Karen Peacock | Director | 2026-05-07 | D | 101 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Karen Peacock | Director | 2026-05-07 | A | 101 | 0 | 0 | Common | Form 4 ↗ |
| Sophie V. Vandebroek, PhD | Director | 2026-05-07 | D | 257 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sophie V. Vandebroek, PhD | Director | 2026-05-07 | A | 257 | 0 | 0 | Common | Form 4 ↗ |
| Daniel M. Junius | Director | 2026-05-07 | A | 257 | 0 | 0 | Common | Form 4 ↗ |
| M. Anne Szostak | Director | 2026-05-07 | A | 257 | 0 | 0 | Common | Form 4 ↗ |
| Joseph L. (Jay) Hooley | Director | 2026-05-07 | D | 158 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel M. Junius | Director | 2026-05-07 | D | 257 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-07 | A | 257 | 0 | 0 | Common | Form 4 ↗ |
| M. Anne Szostak | Director | 2026-05-07 | D | 257 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Irene Chang Britt | Director | 2026-05-12 | A | 525 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stuart M. Essig, PhD | Director | 2026-05-12 | A | 525 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph L. (Jay) Hooley | Director | 2026-05-12 | A | 234 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph L. (Jay) Hooley | Director | 2026-05-12 | A | 525 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-12 | A | 168 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Karen Peacock | Director | 2026-05-12 | A | 525 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sam Samad | Director | 2026-05-12 | A | 234 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sophie V. Vandebroek, PhD | Director | 2026-05-12 | A | 525 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Irene Chang Britt | Director | 2026-05-12 | A | 234 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bruce L. Claflin | Director | 2026-05-12 | A | 234 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stuart M. Essig, PhD | Director | 2026-05-12 | A | 234 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel M. Junius | Director | 2026-05-12 | A | 525 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-12 | A | 75 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-12 | A | 234 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-12 | A | 525 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sam Samad | Director | 2026-05-12 | A | 525 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bruce L. Claflin | Director | 2026-05-12 | A | 525 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel M. Junius | Director | 2026-05-12 | A | 234 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Karen Peacock | Director | 2026-05-12 | A | 234 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sophie V. Vandebroek, PhD | Director | 2026-05-12 | A | 234 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| George Fennell | Executive Vice President | 2026-06-01 | D | 639 | — | — | Derivative, Class A Common | Form 4 ↗ |
| George Fennell | Executive Vice President | 2026-06-01 | D | 284 | 567 | 160,968 | Common | Form 4 ↗ |
| George Fennell | Executive Vice President | 2026-06-01 | A | 639 | 0 | 0 | Common | Form 4 ↗ |
| Joseph L. (Jay) Hooley | Director | 2026-07-30 | A | 49 | 559 | 27,381 | Deferred share award | Form 4 ↗ |
| Andrew Emerson | EVP, CFO and Treasurer | 2026-08-20 | D | 265 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Emerson | EVP, CFO and Treasurer | 2026-08-20 | D | 86 | 0 | 0 | Common | Form 4 ↗ |
| Andrew Emerson | EVP, CFO and Treasurer | 2026-08-20 | A | 265 | 178 | 47,239 | Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-09-04 | D | 2,203 | 532 | 1,172,178 | Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-09-04 | D | 2,203 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-09-04 | A | 2,203 | 114 | 251,517 | Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Michael Lane | RSU | 2025-02-13 | — | — | 1,468 | — | $674,928 |
| Martin Smith | RSU | 2025-02-13 | — | — | 1,468 | — | 674,928 |
| Martin Smith | OPTION | 2025-02-13 | — | — | 6,537 | — | 1,349,949 |
| Tina Hunt | PSU | 2025-02-13 | 294 | 1,468 | — | 2,936 | 674,928 |
| Tina Hunt | OPTION | 2025-02-13 | — | — | 6,537 | — | 1,349,949 |
| Jonathan Mazelsky | OPTION | 2025-02-13 | — | — | 26,149 | — | 5,400,001 |
| Martin Smith | PSU | 2025-02-13 | 294 | 1,468 | — | 2,936 | 674,928 |
| Andrew Emerson | RSU | 2025-02-13 | — | — | 1,033 | — | 474,932 |
| Andrew Emerson | PSU | 2025-02-13 | 207 | 1,033 | — | 2,066 | 474,932 |
| Michael Lane | PSU | 2025-02-13 | 294 | 1,468 | — | 2,936 | 674,928 |
| Michael Lane | OPTION | 2025-02-13 | — | — | 6,537 | — | 1,349,949 |
| Jonathan Mazelsky | PSU | 2025-02-13 | 2,349 | 11,745 | — | 23,490 | 5,399,881 |
| Tina Hunt | RSU | 2025-02-13 | — | — | 1,468 | — | 674,928 |
| Andrew Emerson | OPTION | 2025-02-13 | — | — | 4,600 | — | 949,941 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Michael Lane | $674,928 | $674,928 | $1,349,949 | 25.0% |
| Martin Smith | 674,928 | 674,928 | 1,349,949 | 25.0% |
| Tina Hunt | 674,928 | 674,928 | 1,349,949 | 25.0% |
| Jonathan Mazelsky | 0 | 5,399,881 | 5,400,001 | 50.0% |
| Andrew Emerson | 474,932 | 474,932 | 949,941 | 25.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jonathan Mazelsky | RSU | 9,276 | — | $6,275,492 |
| Brian McKeon | PSU | 928 | — | 627,820 |
| Brian McKeon | RSU | 596 | — | 403,212 |
| Brian McKeon | RSU | 303 | — | 204,989 |
| Tina Hunt | RSU | 204 | — | 138,012 |
| Martin Smith | RSU | 903 | — | 610,907 |
| Michael Lane | RSU | 903 | — | 610,907 |
| Martin Smith | RSU | 1,468 | — | 993,146 |
| Michael Lane | RSU | 1,468 | — | 993,146 |
| Andrew Emerson | RSU | 188 | — | 127,188 |
| Michael Lane | RSU | 204 | — | 138,012 |
| Tina Hunt | RSU | 903 | — | 610,907 |
| Tina Hunt | PSU | 1,204 | — | 814,542 |
| Andrew Emerson | RSU | 125 | — | 84,566 |
| Andrew Emerson | RSU | 1,033 | — | 698,855 |
| Tina Hunt | Option | 6,537 | 459.76 | — |
| Martin Smith | PSU | 1,204 | — | 814,542 |
| Martin Smith | Option | 6,537 | 459.76 | — |
| Andrew Emerson | Option | 4,600 | 459.76 | — |
| Jonathan Mazelsky | Option | 10,728 | 497.43 | — |
| Martin Smith | RSU | 376 | — | 254,375 |
| Michael Lane | RSU | 440 | — | 297,673 |
| Martin Smith | Option | 2,758 | 497.43 | — |
| Michael Lane | Option | 3,218 | 497.43 | — |
| Andrew Emerson | PSU | 167 | — | 112,981 |
| Andrew Emerson | Option | 460 | 497.43 | — |
| Martin Smith | RSU | 148 | — | 100,126 |
| Michael Lane | PSU | 2,936 | — | 1,986,292 |
| Tina Hunt | RSU | 1,468 | — | 993,146 |
| Tina Hunt | PSU | 2,936 | — | 1,986,292 |
| Martin Smith | PSU | 2,936 | — | 1,986,292 |
| Michael Lane | PSU | 1,204 | — | 814,542 |
| Jonathan Mazelsky | RSU | 958 | — | 648,116 |
| Michael Lane | Option | 6,537 | 459.76 | — |
| Jonathan Mazelsky | RSU | 23,490 | — | 15,891,690 |
| Jonathan Mazelsky | Option | 26,149 | 459.76 | — |
| Jonathan Mazelsky | RSU | 2,198 | — | 1,487,013 |
| Andrew Emerson | PSU | 2,066 | — | 1,397,711 |
| Tina Hunt | RSU | 1,508 | — | 1,020,207 |
| Brian McKeon | RSU | 615 | — | 416,066 |
| Tina Hunt | RSU | 414 | — | 280,083 |
| Brian McKeon | Option | 4,506 | 497.43 | — |
| Tina Hunt | Option | 3,034 | 497.43 | — |
Our compensation philosophy is to attract, motivate, focus and retain talented executives who are aligned with, and passionate about, our Purpose: to be a great company that creates exceptional long-term value for our customers, employees and shareholders by enhancing the health and well-being of pets, people and livestock.
| CEO STI target (% of salary) | 130% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Farient |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-12 | 64,399,156 | 3,954,026 | 73,629 | 94.22% | Passed |
| 2025 | 2025-05-07 | 63,288,596 | 4,375,655 | 409,905 | 93.53% | Passed |
| 2024 | 2024-05-06 | 64,265,443 | 4,412,055 | 458,539 | 93.58% | Passed |
| 2023 | 2023-05-17 | 65,447,348 | 3,468,812 | 179,121 | 94.97% | Passed |
| 2022 | 2022-05-11 | 66,515,843 | 3,643,026 | 157,945 | 94.81% | Passed |
| 2021 | 2021-05-12 | 66,390,797 | 3,860,320 | 107,050 | 94.5% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-12 | 94.22%a |
| 2025 | 2025-05-07 | 93.53%b |
| 2024 | 2024-05-06 | 93.58%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes (which are described below) are not counted as votes cast and so have no effect on the outcome of these proposals.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes (which are described below) are not counted as votes cast and so have no effect on the outcome of these proposals.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes (which are described below) are not counted as votes cast and so have no effect on the outcome of the proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 218 : 1 |
|---|---|
| CEO total compensation | $14,580,122 |
| Median employee compensation | $66,956 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Lawrence D. KingsleyIndependent · Board Chair · Lead Independent Director · Compensation and Talent · Governance and Corporate Responsibility | $170,000 | $164,961 | $164,882 | $0 | $0 | $499,842 |
| Irene Chang BrittIndependent · Audit · Compensation and Talent (Chair) | 122,500 | 125,059 | 124,910 | 0 | — | 372,469 |
| M. Anne SzostakIndependent · Audit · Governance and Corporate Responsibility (Chair) | 122,500 | 125,059 | 124,910 | 0 | — | 372,469 |
| Daniel M. JuniusIndependent · Audit (Chair) · Finance | 120,000 | 125,059 | 124,910 | 0 | — | 369,969 |
| Stuart M. Essig, PhDIndependent · Finance (Chair) · Governance and Corporate Responsibility | 105,000 | 125,059 | 124,910 | 0 | — | 354,969 |
| Sam SamadIndependent · Audit · Compensation and Talent | 97,500 | 125,059 | 124,910 | 0 | — | 347,469 |
| Bruce L. ClaflinIndependent · Audit · Compensation and Talent | 97,500 | 125,059 | 124,910 | 0 | — | 347,469 |
| Sophie V. Vandebroek, PhDIndependent · Finance · Governance and Corporate Responsibility | 90,000 | 125,059 | 124,910 | 0 | — | 339,969 |
| Joseph L. (Jay) HooleyIndependent · Audit · Governance and Corporate Responsibility · Newly elected | 46,366 | 102,240 | 102,498 | 0 | 0 | 251,105 |
| Karen PeacockIndependent · Compensation and Talent · Finance · Newly elected | 21,277 | 73,626 | 73,180 | 0 | — | 168,083 |
| Asha S. Collins, PhDIndependent · Departed during FY | 22,500 | — | — | 0 | — | 22,500 |
| Jonathan J. MazelskyEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $90,000 |
|---|---|
| Annual equity retainer | $250,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 30,000 / 25,000 / 25,000 |
| Stock ownership guideline | 6x annual retainer |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $1,015,143 |
| Equity awards (grant-date value) | $1,216,240 |
| All other compensation | $0 |
| Total cost of the board | $2,231,383 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies IDEXX Laboratories names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including IDEXX Laboratories.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Intuitive Surgical, Inc. | 2025 | David Rosa | $858,750 | $18,674,872 | $0 | $1,373,859 | $20,997,480 |
| 2 | Align Technology, Inc. | 2025 | Joseph Hogan | 1,400,000 | 16,556,872 | 0 | 1,220,100 | 19,193,988 |
| 3 | Zoetis Inc. | 2025 | Kristin Peck | 1,350,000 | 10,218,583 | 3,406,229 | 2,187,000 | 19,046,509 |
| 4 | Edwards Lifesciences Corporation | 2025 | Bernard Zovighian | 1,192,500 | 7,167,024 | 6,499,109 | 2,406,537 | 17,454,255 |
| 5 | ResMed Inc. | 2026 | Michael Farrell | 1,272,895 | 9,749,468 | 3,249,907 | 1,738,857 | 16,201,649 |
| 6 | The Cooper Companies, Inc. | 2025 | Albert White III | 1,170,769 | 6,642,918 | 6,643,050 | 1,525,951 | 16,051,141 |
| 7 | Hologic, Inc. | 2024 | Stephen MacMillan | 1,212,628 | 9,141,468 | 2,937,477 | 1,990,413 | 15,819,261 |
| 8 | Elanco Animal Health Incorporated | 2025 | Jeffrey Simmons | 1,200,000 | 9,000,000 | 3,000,004 | 1,700,400 | 14,925,756 |
| 9 | IDEXX Laboratories | 2025 | Jonathan Mazelsky | 1,150,000 | 5,399,881 | 5,400,001 | 2,593,000 | 14,580,122 |
| 10 | Waters Corporation | 2025 | Udit Batra | 1,150,000 | 7,430,247 | 2,999,922 | 2,371,875 | 13,973,044 |
| 11 | Revvity, Inc. | 2025 | Prahlad R. Singh | 1,129,231 | 7,694,985 | 2,559,152 | 2,385,450 | 13,809,549 |
| 12 | Agilent Technologies, Inc. | 2025 | Padraig McDonnell | 1,141,345 | 8,169,850 | 2,017,759 | 1,436,809 | 12,827,236 |
| 13 | STERIS plc | 2026 | Daniel Carestio | 1,095,707 | 4,333,951 | 4,334,251 | 1,725,007 | 11,508,522 |
| 14 | Illumina, Inc. | 2025 | Jacob Thaysen | 1,000,000 | 8,763,122 | 0 | 1,155,000 | 11,018,895 |
| 15 | Bio-Rad Laboratories, Inc. | 2025 | Norman Schwartz | 1,089,877 | 4,856,574 | 1,458,975 | 562,088 | 7,995,841 |
| 16 | DexCom, Inc. | 2025 | Jacob Leach | 768,962 | 5,936,062 | 0 | 1,164,780 | 7,985,960 |
| 17 | Mettler-Toledo International Inc. | 2025 | Patrick Kaltenbach | 1,145,999 | 3,267,808 | 1,635,033 | 462,984 | 6,741,212 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| IDEXX Laboratories | 140% | Options 50 · PSU 50 | No | Farient |
| Agilent Technologies, Inc. | not disclosed | PSU 60 · Options 20 · RSU 20 | No | Semler Brossy |
| Align Technology, Inc. | 58.1% | MSU 70 · RSU 30 | Yes — Relative Total Stockholder Return (TSR) vs. Nasdaq Composite Index | Compensia, Inc. |
| Bio-Rad Laboratories, Inc. | not disclosed | not disclosed | not disclosed | Compensia, Inc. |
| DexCom, Inc. | not disclosed | not disclosed | Yes — Relative TSR Performance Metric | Aon Hewitt Consulting Company |
| Edwards Lifesciences Corporation | 127% | Options 50 · PSU 25 · RSU 25 | No | Semler Brossy Consulting Group |
| Elanco Animal Health Incorporated | not disclosed | not disclosed | No | Willis Towers Watson |
| Hologic, Inc. | 109% | PSU 50 · RSU 25 · Option 25 | No | Pearl Meyer & Partners, LLC |
| Illumina, Inc. | 1155% | not disclosed | Yes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology Index | Aon (Aon's Human Capital Practice, a division of Aon, plc) |
| Intuitive Surgical, Inc. | 115.2% | RSU 50 · PSU 50 | No | Aon |
| Mettler-Toledo International Inc. | not disclosed | not disclosed | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners |
| ResMed Inc. | not disclosed | PSU 50 · RSU 25 · Options 25 | Yes — Relative TSR | FW Cook |
| Revvity, Inc. | 124% | PSU 50 · RSU 25 · Options 25 | No | Pearl Meyer |
| STERIS plc | 125.1% | RSU 50 · Options 50 | not disclosed | Frederic W. Cook & Co., Inc. |
| The Cooper Companies, Inc. | 100.9% | Options 50 · PSU 50 | No | Compensia |
| Waters Corporation | 110% | PSU 50 · Options 35 · RSU 15 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer |
| Zoetis Inc. | 108% | PSU 50 · Options 25 · RSU 25 | Yes — Relative TSR | Pearl Meyer |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Jonathan Mazelsky | DEF 14A | 2026-03-27 | 0000874716-26-000064 | Section “Summary Compensation Table for 2025”. As printed: 14,580,122. Filing ↗machine: span 1576008–1576018 |
| 2 | Section 01, Michael Lane | DEF 14A | 2026-03-27 | 0000874716-26-000064 | Section “Summary Compensation Table for 2025”. As printed: 4,019,416. Filing ↗machine: span 1592569–1592578 |
| 3 | Section 01, Tina Hunt | DEF 14A | 2026-03-27 | 0000874716-26-000064 | Section “Summary Compensation Table for 2025”. As printed: 3,945,293. Filing ↗machine: span 1604543–1604552 |
| 4 | Section 01, Martin Smith | DEF 14A | 2026-03-27 | 0000874716-26-000064 | Section “Summary Compensation Table for 2025”. As printed: 3,944,534. Filing ↗machine: span 1616717–1616726 |
| 5 | Section 01, Andrew Emerson | DEF 14A | 2026-03-27 | 0000874716-26-000064 | Section “Summary Compensation Table for 2025”. As printed: 3,033,071. Filing ↗machine: span 1588033–1588042 |
| 6 | Section 01, Brian McKeon | DEF 14A | 2026-03-27 | 0000874716-26-000064 | Section “Summary Compensation Table for 2025”. As printed: 351,680. Filing ↗machine: span 1625140–1625147 |
| 7 | Section 03, Michael Lane RSU | DEF 14A | 1900-01-01 | 0000874716-26-000064 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1693665–1693672 |
| 8 | Section 03, Martin Smith RSU | DEF 14A | 1900-01-01 | 0000874716-26-000064 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1730563–1730570 |
| 9 | Section 03, Martin Smith OPTION | DEF 14A | 1900-01-01 | 0000874716-26-000064 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1735143–1735152 |
| 10 | Section 03, Tina Hunt PSU | DEF 14A | 1900-01-01 | 0000874716-26-000064 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1707619–1707626 |
| 11 | Section 03, Tina Hunt OPTION | DEF 14A | 1900-01-01 | 0000874716-26-000064 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1716780–1716789 |
| 12 | Section 03, Jonathan Mazelsky OPTION | DEF 14A | 1900-01-01 | 0000874716-26-000064 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1661114–1661123 |
| 13 | Section 03, Martin Smith PSU | DEF 14A | 1900-01-01 | 0000874716-26-000064 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1725982–1725989 |
| 14 | Section 03, Andrew Emerson RSU | DEF 14A | 1900-01-01 | 0000874716-26-000064 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1675073–1675080 |
| 15 | Section 03, Andrew Emerson PSU | DEF 14A | 1900-01-01 | 0000874716-26-000064 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1670434–1670441 |
| 16 | Section 03, Michael Lane PSU | DEF 14A | 1900-01-01 | 0000874716-26-000064 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1689026–1689033 |
| 17 | Section 03, Michael Lane OPTION | DEF 14A | 1900-01-01 | 0000874716-26-000064 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1698303–1698312 |
| 18 | Section 03, Jonathan Mazelsky PSU | DEF 14A | 1900-01-01 | 0000874716-26-000064 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1656587–1656596 |
| 19 | Section 03, Tina Hunt RSU | DEF 14A | 1900-01-01 | 0000874716-26-000064 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1712200–1712207 |
| 20 | Section 03, Andrew Emerson OPTION | DEF 14A | 1900-01-01 | 0000874716-26-000064 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1679711–1679718 |
| 21 | Section 07, pay ratio | DEF 14A | 2026-03-27 | 0000874716-26-000064 | Section “CEO Pay Ratio”. As printed: 218 : 1. Filing ↗machine: span 2135068–2135076 |
| 22 | Section 08, Lawrence D. Kingsley | DEF 14A | 2026-03-27 | 0000874716-26-000064 | Section “Director Compensation”. As printed: 499,842. Filing ↗machine: t143 · r9 · c10 · span 977088–977269 |
| 23 | Section 08, Irene Chang Britt | DEF 14A | 2026-03-27 | 0000874716-26-000064 | Section “Director Compensation”. As printed: 372,469. Filing ↗machine: t143 · r3 · c10 · span 960115–960296 |
| 24 | Section 08, M. Anne Szostak | DEF 14A | 2026-03-27 | 0000874716-26-000064 | Section “Director Compensation”. As printed: 372,469. Filing ↗machine: t143 · r12 · c10 · span 985459–985640 |
| 25 | Section 08, Daniel M. Junius | DEF 14A | 2026-03-27 | 0000874716-26-000064 | Section “Director Compensation”. As printed: 369,969. Filing ↗machine: t143 · r8 · c10 · span 974358–974539 |
| 26 | Section 08, Stuart M. Essig, PhD | DEF 14A | 2026-03-27 | 0000874716-26-000064 | Section “Director Compensation”. As printed: 354,969. Filing ↗machine: t143 · r6 · c10 · span 968443–968624 |
| 27 | Section 08, Sam Samad | DEF 14A | 2026-03-27 | 0000874716-26-000064 | Section “Director Compensation”. As printed: 347,469. Filing ↗machine: t143 · r11 · c10 · span 982730–982911 |
| 28 | Section 08, Bruce L. Claflin | DEF 14A | 2026-03-27 | 0000874716-26-000064 | Section “Director Compensation”. As printed: 347,469. Filing ↗machine: t143 · r4 · c10 · span 962781–962962 |
| 29 | Section 08, Sophie V. Vandebroek, PhD | DEF 14A | 2026-03-27 | 0000874716-26-000064 | Section “Director Compensation”. As printed: 339,969. Filing ↗machine: t143 · r13 · c10 · span 988536–988717 |
| 30 | Section 08, Joseph L. (Jay) Hooley | DEF 14A | 2026-03-27 | 0000874716-26-000064 | Section “Director Compensation”. As printed: 251,105. Filing ↗machine: t143 · r7 · c10 · span 971629–971810 |
| 31 | Section 08, Karen Peacock | DEF 14A | 2026-03-27 | 0000874716-26-000064 | Section “Director Compensation”. As printed: 168,083. Filing ↗machine: t143 · r10 · c10 · span 980010–980191 |
| 32 | Section 08, Asha S. Collins, PhD | DEF 14A | 2026-03-27 | 0000874716-26-000064 | Section “Director Compensation”. As printed: 22,500. Filing ↗machine: t143 · r5 · c1 · span 963783–963963 |
| 33 | Section 08, Jonathan J. Mazelsky | DEF 14A | 2026-03-27 | 0000874716-26-000064 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 34 | Section 02, Joseph L. (Jay) Hooley 2026-04-30 | Form 4 | 2026-05-04 | 0000874716-26-000069 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Joseph L. (Jay) Hooley 2026-05-07 | Form 4 | 2026-05-11 | 0000874716-26-000083 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Lawrence D. Kingsley 2026-05-07 | Form 4 | 2026-05-11 | 0000874716-26-000085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Lawrence D. Kingsley 2026-05-07 | Form 4 | 2026-05-11 | 0000874716-26-000085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Lawrence D. Kingsley 2026-05-07 | Form 4 | 2026-05-11 | 0000874716-26-000085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Karen Peacock 2026-05-07 | Form 4 | 2026-05-11 | 0000874716-26-000086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Karen Peacock 2026-05-07 | Form 4 | 2026-05-11 | 0000874716-26-000086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Sophie V. Vandebroek, PhD 2026-05-07 | Form 4 | 2026-05-11 | 0000874716-26-000088 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Sophie V. Vandebroek, PhD 2026-05-07 | Form 4 | 2026-05-11 | 0000874716-26-000088 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Daniel M. Junius 2026-05-07 | Form 4 | 2026-05-11 | 0000874716-26-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, M. Anne Szostak 2026-05-07 | Form 4 | 2026-05-11 | 0000874716-26-000087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Joseph L. (Jay) Hooley 2026-05-07 | Form 4 | 2026-05-11 | 0000874716-26-000083 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Daniel M. Junius 2026-05-07 | Form 4 | 2026-05-11 | 0000874716-26-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Lawrence D. Kingsley 2026-05-07 | Form 4 | 2026-05-11 | 0000874716-26-000085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, M. Anne Szostak 2026-05-07 | Form 4 | 2026-05-11 | 0000874716-26-000087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Irene Chang Britt 2026-05-12 | Form 4 | 2026-05-14 | 0000874716-26-000099 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Stuart M. Essig, PhD 2026-05-12 | Form 4 | 2026-05-14 | 0000874716-26-000101 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Joseph L. (Jay) Hooley 2026-05-12 | Form 4 | 2026-05-14 | 0000874716-26-000102 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Joseph L. (Jay) Hooley 2026-05-12 | Form 4 | 2026-05-14 | 0000874716-26-000102 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Lawrence D. Kingsley 2026-05-12 | Form 4 | 2026-05-14 | 0000874716-26-000104 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Karen Peacock 2026-05-12 | Form 4 | 2026-05-14 | 0000874716-26-000105 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Sam Samad 2026-05-12 | Form 4 | 2026-05-14 | 0000874716-26-000106 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Sophie V. Vandebroek, PhD 2026-05-12 | Form 4 | 2026-05-14 | 0000874716-26-000107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Irene Chang Britt 2026-05-12 | Form 4 | 2026-05-14 | 0000874716-26-000099 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Bruce L. Claflin 2026-05-12 | Form 4 | 2026-05-14 | 0000874716-26-000100 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Stuart M. Essig, PhD 2026-05-12 | Form 4 | 2026-05-14 | 0000874716-26-000101 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Daniel M. Junius 2026-05-12 | Form 4 | 2026-05-14 | 0000874716-26-000103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Lawrence D. Kingsley 2026-05-12 | Form 4 | 2026-05-14 | 0000874716-26-000104 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Lawrence D. Kingsley 2026-05-12 | Form 4 | 2026-05-14 | 0000874716-26-000104 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Lawrence D. Kingsley 2026-05-12 | Form 4 | 2026-05-14 | 0000874716-26-000104 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Sam Samad 2026-05-12 | Form 4 | 2026-05-14 | 0000874716-26-000106 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Bruce L. Claflin 2026-05-12 | Form 4 | 2026-05-14 | 0000874716-26-000100 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Daniel M. Junius 2026-05-12 | Form 4 | 2026-05-14 | 0000874716-26-000103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Karen Peacock 2026-05-12 | Form 4 | 2026-05-14 | 0000874716-26-000105 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Sophie V. Vandebroek, PhD 2026-05-12 | Form 4 | 2026-05-14 | 0000874716-26-000107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, George Fennell 2026-06-01 | Form 4 | 2026-06-02 | 0000874716-26-000114 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, George Fennell 2026-06-01 | Form 4 | 2026-06-02 | 0000874716-26-000114 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, George Fennell 2026-06-01 | Form 4 | 2026-06-02 | 0000874716-26-000114 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Joseph L. (Jay) Hooley 2026-07-30 | Form 4 | 2026-08-03 | 0000874716-26-000117 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Andrew Emerson 2026-08-20 | Form 4 | 2026-08-24 | 0000874716-26-000125 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Andrew Emerson 2026-08-20 | Form 4 | 2026-08-24 | 0000874716-26-000125 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Andrew Emerson 2026-08-20 | Form 4 | 2026-08-24 | 0000874716-26-000125 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Lawrence D. Kingsley 2026-09-04 | Form 4 | 2026-09-09 | 0000874716-26-000127 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Lawrence D. Kingsley 2026-09-04 | Form 4 | 2026-09-09 | 0000874716-26-000127 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Lawrence D. Kingsley 2026-09-04 | Form 4 | 2026-09-09 | 0000874716-26-000127 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 06, 2026 vote | Form 8-K | 2026-05-15 | 0000874716-26-000110 | Item 5.07 · say-on-pay result. As reported: 94.22% (votes for as printed: 64,399,156). Filing ↗ |
| 80 | Section 06, 2025 vote | Form 8-K | 2025-05-09 | 0000874716-25-000085 | Item 5.07 · say-on-pay result. As reported: 93.53% (votes for as printed: 63,288,596). Filing ↗ |
| 81 | Section 06, 2024 vote | Form 8-K | 2024-05-10 | 0000874716-24-000107 | Item 5.07 · say-on-pay result. As reported: 93.58% (votes for as printed: 64,265,443). Filing ↗ |
| 82 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 83 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 84 | Section 09b board cost (computed) | Computed | — | — | Cash 1,015,143 + equity 1,216,240 + all other 0 = 2,231,383, summed across the director compensation table rows.machine: formula: Σ = 2,231,383 |
| 85 | Intuitive Surgical, Inc., Section 10b CEO total | DEF 14A | 2026-03-13 | 0001035267-26-000023 | CEO total compensation as printed in Intuitive Surgical, Inc.'s own proxy. As printed: 20,997,480. Filing ↗machine: r2 · c48 · span 762289–762299 |
| 86 | Align Technology, Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001097149-26-000023 | CEO total compensation as printed in Align Technology, Inc.'s own proxy. As printed: 19,193,988. Filing ↗machine: r2 · c42 · span 933168–933178 |
| 87 | Zoetis Inc., Section 10b CEO total | DEF 14A | 2026-04-08 | 0001555280-26-000015 | CEO total compensation as printed in Zoetis Inc.'s own proxy. As printed: 19,046,509. Filing ↗machine: r3 · c24 · span 1448788–1448798 |
| 88 | Edwards Lifesciences Corporation, Section 10b CEO total | DEF 14A | 2026-03-26 | 0001099800-26-000015 | CEO total compensation as printed in Edwards Lifesciences Corporation's own proxy. As printed: 17,454,255. Filing ↗machine: r2 · c27 · span 965441–965451 |
| 89 | ResMed Inc., Section 10b CEO total | DEF 14A | 2026-10-01 | 0000943819-26-000080 | CEO total compensation as printed in ResMed Inc.'s own proxy. As printed: 16,201,649. Filing ↗machine: span 1267106–1267116 |
| 90 | The Cooper Companies, Inc., Section 10b CEO total | DEF 14A | 2026-02-24 | 0001628280-26-011110 | CEO total compensation as printed in The Cooper Companies, Inc.'s own proxy. As printed: 16,051,141. Filing ↗machine: t120 · r3 · c14 · span 744904–744914 |
| 91 | Hologic, Inc., Section 10b CEO total | DEF 14A | 2025-01-16 | 0001140361-25-001287 | CEO total compensation as printed in Hologic, Inc.'s own proxy. As printed: 15,819,261. Filing ↗machine: r2 · c25 · span 1549664–1549674 |
| 92 | Elanco Animal Health Incorporated, Section 10b CEO total | DEF 14A | 2026-04-08 | 0001739104-26-000016 | CEO total compensation as printed in Elanco Animal Health Incorporated's own proxy. As printed: 14,925,756. Filing ↗machine: r4 · c24 · span 1067844–1067854 |
| 93 | IDEXX Laboratories (subject), Section 10b CEO total | DEF 14A | 2026-03-27 | 0000874716-26-000064 | CEO total compensation as printed in IDEXX Laboratories's own proxy. As printed: 14,580,122. Filing ↗machine: span 1576008–1576018 |
| 94 | Waters Corporation, Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149657 | CEO total compensation as printed in Waters Corporation's own proxy. As printed: 13,973,044. Filing ↗machine: r5 · c18 · span 568522–568533 |
| 95 | Revvity, Inc., Section 10b CEO total | DEF 14A | 2026-03-16 | 0001193125-26-107266 | CEO total compensation as printed in Revvity, Inc.'s own proxy. As printed: 13,809,549. Filing ↗machine: r3 · c39 · span 751285–751295 |
| 96 | Agilent Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-02-06 | 0001193125-26-040286 | CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. Filing ↗machine: r3 · c29 · span 1450982–1450992 |
| 97 | STERIS plc, Section 10b CEO total | DEF 14A | 2026-06-11 | 0001193125-26-267599 | CEO total compensation as printed in STERIS plc's own proxy. As printed: 11,508,522. Filing ↗machine: t172 · r6 · c34 · span 820590–820600 |
| 98 | Illumina, Inc., Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149669 | CEO total compensation as printed in Illumina, Inc.'s own proxy. As printed: 11,018,895. Filing ↗machine: r4 · c14 · span 728526–728536 |
| 99 | Bio-Rad Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-03-25 | 0000012208-26-000020 | CEO total compensation as printed in Bio-Rad Laboratories, Inc.'s own proxy. As printed: 7,995,841. Filing ↗machine: r2 · c24 · span 654200–654209 |
| 100 | DexCom, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0001093557-26-000061 | CEO total compensation as printed in DexCom, Inc.'s own proxy. As printed: 7,985,960. Filing ↗machine: span 940364–940373 |
| 101 | Mettler-Toledo International Inc., Section 10b CEO total | DEF 14A | 2026-03-18 | 0001174947-26-000389 | CEO total compensation as printed in Mettler-Toledo International Inc.'s own proxy. As printed: 6,741,212. Filing ↗machine: r2 · c7 · span 643529–643538 |
| 102 | Section 10a, The Cooper Companies, Inc. reciprocity | DEF 14A | — | 0001628280-26-011110 | The Cooper Companies, Inc.'s most recent proxy was read; its disclosed peer group does not include IDEXX Laboratories. Filing ↗ |
| 103 | Section 10a, DexCom, Inc. reciprocity | DEF 14A | — | 0001093557-26-000061 | DexCom, Inc. names IDEXX Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 104 | Section 10a, STERIS plc reciprocity | DEF 14A | — | 0001193125-26-267599 | STERIS plc names IDEXX Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 105 | Section 10a, Waters Corporation reciprocity | DEF 14A | — | 0001193125-26-149657 | Waters Corporation names IDEXX Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 106 | Section 10a, Hologic, Inc. reciprocity | DEF 14A | — | 0001140361-25-001287 | Hologic, Inc. names IDEXX Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 107 | Section 10a, Zoetis Inc. reciprocity | DEF 14A | — | 0001555280-26-000015 | Zoetis Inc. names IDEXX Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 108 | Section 10a, Agilent Technologies, Inc. reciprocity | DEF 14A | — | 0001193125-26-040286 | Agilent Technologies, Inc. names IDEXX Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 109 | Section 10a, ResMed Inc. reciprocity | DEF 14A | — | 0000943819-26-000080 | ResMed Inc. names IDEXX Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 110 | Section 10a, Align Technology, Inc. reciprocity | DEF 14A | — | 0001097149-26-000023 | Align Technology, Inc. names IDEXX Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 111 | Section 10a, Edwards Lifesciences Corporation reciprocity | DEF 14A | — | 0001099800-26-000015 | Edwards Lifesciences Corporation names IDEXX Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 112 | Section 10a, Elanco Animal Health Incorporated reciprocity | DEF 14A | — | 0001739104-26-000016 | Elanco Animal Health Incorporated names IDEXX Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 113 | Section 10a, Mettler-Toledo International Inc. reciprocity | DEF 14A | — | 0001174947-26-000389 | Mettler-Toledo International Inc.'s most recent proxy was read; its disclosed peer group does not include IDEXX Laboratories. Filing ↗ |
| 114 | Section 10a, Revvity, Inc. reciprocity | DEF 14A | — | 0001193125-26-107266 | Revvity, Inc.'s most recent proxy was read; its disclosed peer group does not include IDEXX Laboratories. Filing ↗ |
| 115 | Section 10a, Intuitive Surgical, Inc. reciprocity | DEF 14A | — | 0001035267-26-000023 | Intuitive Surgical, Inc. names IDEXX Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.